Dermata sets August 25 launch for Tome skincare product, reports Q2 2026 results
Dermata Therapeutics said its first direct-to-consumer skincare product, Tome Foundational Treatment, is set to launch on August 25, 2026, as it reported second-quarter financials.
Dermata Therapeutics said on August 11, 2026 that it expects to begin selling its first commercial product, Tome Foundational Treatment, on August 25, 2026.1 The company said it has finished manufacturing and packaging for the product and is prepared for the commercial launch.1 Dermata described Tome Foundational Treatment as designed to renew the appearance of the skin with a once-weekly application.1
The company also said it is working on a follow-on product. Dermata is developing a second skincare product, a once-weekly, over-the-counter topical treatment for acne, which is expected to launch sometime after the Foundational Treatment.1
In June 2026, Dermata attended a trade show to promote the new line. The company exhibited at the Be+Well Beauty and Wellness Show to officially launch the Tome brand and inform attendees about the upcoming Foundational Treatment launch, at a conference that hosts thousands of professionals and more than 400 brands.1 Dermata also said it unveiled the Tome brand's official social media presence as part of its broader commercial launch strategy.1
On financials, Dermata reported $4.4 million in cash and cash equivalents as of June 30, 2026, compared with $7.5 million as of December 31, 2025.1 The company attributed the $3.1 million six-month decline in cash to $4.9 million used in operations and $0.1 million used in investing activities, partly offset by about $1.9 million in proceeds from an at-the-market financing program.1 Dermata said it expects its current cash resources to fund operations into the fourth quarter of 2026.1
Research and development spending fell as the company shifted resources. Research and development expenses were $0.2 million for the quarter ended June 30, 2026, versus $0.6 million a year earlier, a decrease the company attributed to prioritizing the commercial launch over R&D efforts.1 Selling, general and administrative expenses rose to $2.8 million for the quarter, compared with $1.2 million in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.